/

/

Cybin Reports Positive Topline Data from Phase 2 Study of Major Depressive Disorder

Thu, Nov 30

Potentially groundbreaking results as Cybin's Phase 2 Study of CYB003 in Major Depressive Disorder showed 79% of patients in remission after two 12mg doses. https://t.co/9gjPI3jq8s

122745

Cybin's Phase 2 Study of CYB003 in Major Depressive Disorder showed 79% of patients in remission after two 12mg doses.

Discover